

包括的なソリューションで  
オルガノイド研究を強力にサポート!



Scan to Download the  
Organoid Toolbox Brochure


iPSC (人工多能性幹細胞) 由来のオルガノイド技術の活用によって、バイオメディカル分野、特に創薬、疾患モデリング、個別化医療、再生医療において、計り知れない可能性と明るい将来を示されています。

ACROBiosystemsは、ready-to-use型のオルガノイド、オルガノイド分化キット、凍結保存オルガノイド、凍結保存培地、カスタマイズされたサービスなど包括的なオルガノイドソリューションを提供し、オルガノイドの幅広い応用への探求を支援します!


## 安心サービス:オルガノイド製品の輸送もお任せください。

目的地や輸送時間を十分に配慮し、到着後すぐに使用できるようにオルガノイド製品を準備しております。


## 当社で提供されるサービス




Cardiac-related  
Solutions & Services



Cerebral-related  
Solutions & Services



Intestinal-related  
Solutions & Services




Liver-related  
Solutions & Services

Product Type	Cat. No.	Product Description
Cardiac Organoid	CIPO-HWL002K	Ready-to-use Human iPSC-Derived Cardiac Organoids
	RIPO-HWM002K	Human iPSC-Derived Cardiac Organoid Differentiation Kit
	RIPO-HWM004	Human iPSC-Derived Cardiac Organoid Maintenance Kit
	RIPO-HWM005	Cardiac Organoid Cryopreservation Kit
Cerebral Organoid	CIPO-BWL001K	Ready-to-use Human iPSC-Derived Cerebral Organoids
	CIPO-BWL001KC	Cryopreserved Human iPSC-Derived Cerebral Organoids
	RIPO-BWM001K	Human iPSC-Derived Cerebral Organoid Differentiation Kit
	RIPO-BWM003	Human iPSC-Derived Cerebral Organoid Maturation and Maintenance Kit
	RIPO-BWM006	Cerebral Organoid Cryopreservation Kit
Intestinal Organoid	CIPO-IWL003K	Ready-to-use Human iPSC-Derived Intestinal Organoids
	RIPO-IWM005K	Human iPSC-Derived Intestinal Organoid Differentiation Kit
	RIPO-IWM006	Human iPSC-Derived Intestinal Organoid Maintenance Kit
Liver Organoid	CIPO-RWL005K	Ready-to-use Human iPSC-Derived Liver Organoids
	RIPO-RWM009K	Human iPSC-Derived Liver Organoid Differentiation Kit
	RIPO-RWM010	Human iPSC-Derived Liver Organoid Expansion and Maintenance medium


## 検証データ

### ・薬物スクリーニングに使用された心臓オルガノイド




The Cardiac Organoids (Cat. No. CIPO-HWL002K) differentiated using the Human iPSC-Derived Cardiac Organoid Differentiation Kit (Cat. No. RIPO-HWM002K) structure of the cardiac organoids cultured for 20 days were used in screening for heart injury drugs. Drug A caused damage to the vascular.

### ・アルツハイマー病モデル作製に使用された大脳オルガノイド




The Cerebral Organoids (Cat. No. CIPO-BWL001K) differentiated using the Human iPSC-Derived Cerebral Organoid Differentiation Kit (Cat. No. RIPO-BWM001K) grew for 55 days and were treated with Tau-441 K18(P301L) Pre-formed Fibrils (Cat. No. TAU-H5113) at concentrations of 100 ug/ml and 500 ug/ml for 5 days. This treatment was used to generate an Alzheimer's Disease (AD) model. A key pathological feature of AD is the accumulation of phosphorylated tau (pTau). Upon treatment with Tau PFFs, immunostaining revealed an increased accumulation of p-Tau181, indicating the induction of an AD phenotype.

### ・腸オルガノイドの機能検証



The Intestinal Organoids (Cat. No. CIPO-IWL003K) differentiated using the Human iPSC-Derived Intestinal Organoid Differentiation Kit (Cat. No. RIPO-IWM005K) can absorb fatty acids and glucose.

### ・肝オルガノイドのトランスクリプトーム解析



The Liver Organoids (Cat. No. CIPO-RWL005K) differentiated by using the Human iPSC-Derived Liver Organoid Differentiation Kit (Cat. No. RIPO-RWM009K) expressed hepatic marker (ALB), cholangiocyte marker (CK19) and endothelial marker (CD31) at day 34. (Scale bar: 250µm).